stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Total debt
Lakefront Biotherapeutics - Sponsored ADR's total debt at the end of fiscal 2025 was $5.9M, up 9.65% from $5.4M in fiscal 2023. At the end of the quarter to 30 June 2026 it was $5.5M. Over the past ten years it has ranged from $0.00 (fiscal 2017) to $28.4M (fiscal 2020); the current reading is higher than 56% of that period. Lakefront Biotherapeutics - Sponsored ADR ranks 280th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $5.9M | 9.65% |
| FY2023 | $5.4M | (65.43%) |
| FY2022 | $15.5M | (31.89%) |
| FY2021 | $22.7M | (19.96%) |
| FY2020 | $28.4M | 26.36% |
| FY2019 | $22.5M | — |
| FY2017 | $0.00 | — |
| FY2016 | $10.0K | (85.71%) |
| FY2015 | $70.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $5.5M | (2.25%) |
| Mar 2026 | $5.7M | (17.33%) |
| Jun 2025 | $6.9M | 64.87% |
| Mar 2024 | $4.2M | (54.81%) |
| 24 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| VCEL Vericel Corporation compare | $85.1M |
| VERA Vera Therapeutics, Inc. compare | $75.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $39.0M |
| PVLA Palvella Therapeutics, Inc. compare | $12.3M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $5.5M |
| ZYME Zymeworks Inc. compare | $278.0K |
| IMNM Immunome, Inc. compare | $228.0K |
| SEPN Septerna, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement